The features of infectious diseases departments and anti-infective practices in France and Turkey: A cross-sectional study
dc.contributor.buuauthor | Heper, Yasemin | |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı. | tr_TR |
dc.contributor.researcherid | AAH-6506-2021 | tr_TR |
dc.contributor.scopusid | 56191003300 | tr_TR |
dc.date.accessioned | 2024-02-15T07:35:06Z | |
dc.date.available | 2024-02-15T07:35:06Z | |
dc.date.issued | 2014-04-08 | |
dc.description | Çalışmada 43 yazar bulunmaktadır. Bu yazarlardan sadece Bursa Uludağ Üniversitesi mensuplarının girişleri yapılmıştır. | tr_TR |
dc.description.abstract | The aim of this study was to assess the infectious diseases (ID) wards of tertiary hospitals in France and Turkey for technical capacity, infection control, characteristics of patients, infections, infecting organisms, and therapeutic approaches. This cross-sectional study was carried out on a single day on one of the weekdays of June 17-21, 2013. Overall, 36 ID departments from Turkey (n = 21) and France (n = 15) were involved. On the study day, 273 patients were hospitalized in Turkish and 324 patients were followed in French ID departments. The numbers of patients and beds in the hospitals, and presence of an intensive care unit (ICU) room in the ID ward was not different in both France and Turkey. Bed occupancy in the ID ward, single rooms, and negative pressure rooms were significantly higher in France. The presence of a laboratory inside the ID ward was more common in Turkish ID wards. The configuration of infection control committees, and their qualifications and surveillance types were quite similar in both countries. Although differences existed based on epidemiology, the distribution of infections were uniform on both sides. In Turkey, anti-Gram-positive agents, carbapenems, and tigecycline, and in France, cephalosporins, penicillins, aminoglycosides, and metronidazole were more frequently preferred. Enteric Gram-negatives and hepatitis B and C were more frequent in Turkey, while human immunodeficiency virus (HIV) and streptococci were more common in France (p < 0.05 for all significances). Various differences and similarities existed in France and Turkey in the ID wards. However, the current scene is that ID are managed with high standards in both countries. | en_US |
dc.identifier.citation | Erdem, H. vd. (2014). "The features of infectious diseases departments and anti-infective practices in France and Turkey: A cross-sectional study". European Journal of Clinical Microbiology and Infectious Diseases, 33(9), 1591-1599. | en_US |
dc.identifier.doi | https://doi.org/10.1007/s10096-014-2116-9 | en_US |
dc.identifier.eissn | 1435-4373 | |
dc.identifier.endpage | 1599 | tr_TR |
dc.identifier.issn | 0934-9723 | |
dc.identifier.issue | 9 | tr_TR |
dc.identifier.pubmed | 24789652 | tr_TR |
dc.identifier.scopus | 2-s2.0-84906062372 | tr_TR |
dc.identifier.startpage | 1591 | tr_TR |
dc.identifier.uri | https://link.springer.com/article/10.1007/s10096-014-2116-9 | en_US |
dc.identifier.uri | https://hdl.handle.net/11452/39744 | en_US |
dc.identifier.volume | 33 | tr_TR |
dc.identifier.wos | 000340538700017 | tr_TR |
dc.indexed.wos | SCIE | en_US |
dc.language.iso | en | en_US |
dc.publisher | Springer | en_US |
dc.relation.collaboration | Yurt içi | tr_TR |
dc.relation.collaboration | Yurt dışı | tr_TR |
dc.relation.collaboration | Sanayi | tr_TR |
dc.relation.journal | European Journal of Clinical Microbiology and Infectious Diseases | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Intensive-care units | en_US |
dc.subject | Hospitals | en_US |
dc.subject | Point prevalence | en_US |
dc.subject | Infectious diseases | en_US |
dc.subject | Microbiology | en_US |
dc.subject.emtree | Abscess | en_US |
dc.subject.emtree | Acinetobacter baumannii | en_US |
dc.subject.emtree | Aggregatibacter actinomycetemcomitans | en_US |
dc.subject.emtree | Antibiotic prophylaxis | en_US |
dc.subject.emtree | Antimicrobial therapy | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Aspergillus | en_US |
dc.subject.emtree | Bacillus cereus | en_US |
dc.subject.emtree | Bacterial endocarditis | en_US |
dc.subject.emtree | Bone infection | en_US |
dc.subject.emtree | Brucella | en_US |
dc.subject.emtree | Brucellosis | en_US |
dc.subject.emtree | Campylobacter | en_US |
dc.subject.emtree | Candida | en_US |
dc.subject.emtree | Central nervous system infection | en_US |
dc.subject.emtree | Cholangitis | en_US |
dc.subject.emtree | Cholecystitis | en_US |
dc.subject.emtree | Clinical practice | en_US |
dc.subject.emtree | Clostridium | en_US |
dc.subject.emtree | Colitis | en_US |
dc.subject.emtree | Corynebacterium | en_US |
dc.subject.emtree | Creutzfeldt jakob disease | en_US |
dc.subject.emtree | Crimean congo hemorrhagic fever | en_US |
dc.subject.emtree | Cross-sectional study | en_US |
dc.subject.emtree | Cryptococcus | en_US |
dc.subject.emtree | Cytomegalovirus infection | en_US |
dc.subject.emtree | Diabetic foot | en_US |
dc.subject.emtree | Disease severity | en_US |
dc.subject.emtree | Disease surveillance | en_US |
dc.subject.emtree | Enterococcus | en_US |
dc.subject.emtree | Enterovirus infection | en_US |
dc.subject.emtree | France | en_US |
dc.subject.emtree | Gastroenteritis | en_US |
dc.subject.emtree | Haemophilus | en_US |
dc.subject.emtree | Health care personnel | en_US |
dc.subject.emtree | Hepatitis b | en_US |
dc.subject.emtree | Hepatitis c | en_US |
dc.subject.emtree | Hospital bed capacity | en_US |
dc.subject.emtree | Hospital bed utilization | en_US |
dc.subject.emtree | Hospital hygiene | en_US |
dc.subject.emtree | Hospital laboratory | en_US |
dc.subject.emtree | Hospital patient | en_US |
dc.subject.emtree | Hospital waste | en_US |
dc.subject.emtree | Hospitalization | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Human immunodeficiency virus infection | en_US |
dc.subject.emtree | Infection | en_US |
dc.subject.emtree | Infection control | en_US |
dc.subject.emtree | Infection prevention | en_US |
dc.subject.emtree | Infectious arthritis | en_US |
dc.subject.emtree | Infectious diseases ward | en_US |
dc.subject.emtree | Intensive care unit | en_US |
dc.subject.emtree | Legionella | en_US |
dc.subject.emtree | Leptospira | en_US |
dc.subject.emtree | Major clinical study | en_US |
dc.subject.emtree | Malaria | en_US |
dc.subject.emtree | Measles | en_US |
dc.subject.emtree | Measles virus | en_US |
dc.subject.emtree | Mycobacterium intracellulare avium | en_US |
dc.subject.emtree | Mycobacterium tuberculosis | en_US |
dc.subject.emtree | Neisseria | en_US |
dc.subject.emtree | Nurse | en_US |
dc.subject.emtree | Plasmodium falciparum | en_US |
dc.subject.emtree | Pneumonia | en_US |
dc.subject.emtree | Priority journal | en_US |
dc.subject.emtree | Protective equipment | en_US |
dc.subject.emtree | Pseudomonas aeruginosa | en_US |
dc.subject.emtree | Rna virus infection | en_US |
dc.subject.emtree | Room ventilation | en_US |
dc.subject.emtree | Sepsis | en_US |
dc.subject.emtree | Septic shock | en_US |
dc.subject.emtree | Skin infection | en_US |
dc.subject.emtree | Soft tissue infection | en_US |
dc.subject.emtree | Staphylococcus aureus | en_US |
dc.subject.emtree | Streptococcus | en_US |
dc.subject.emtree | Streptococcus infection | en_US |
dc.subject.emtree | Surgical infection | en_US |
dc.subject.emtree | Syphilis | en_US |
dc.subject.emtree | Tertiary care center | en_US |
dc.subject.emtree | Treponema pallidum | en_US |
dc.subject.emtree | Tuberculosis | en_US |
dc.subject.emtree | Turkey (republic) | en_US |
dc.subject.emtree | Upper respiratory tract infection | en_US |
dc.subject.emtree | Urinary tract infection | en_US |
dc.subject.emtree | Vaccination | en_US |
dc.subject.emtree | Virus hepatitis | en_US |
dc.subject.emtree | Ward | en_US |
dc.subject.emtree | Waste management | en_US |
dc.subject.emtree | Adult | en_US |
dc.subject.emtree | Aged | en_US |
dc.subject.emtree | Communicable diseases | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | France | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Middle aged | en_US |
dc.subject.emtree | Patient care | en_US |
dc.subject.emtree | Procedures | en_US |
dc.subject.emtree | Standards | en_US |
dc.subject.emtree | Turkey | en_US |
dc.subject.emtree | Aminoglycoside | en_US |
dc.subject.emtree | Ampicillin | en_US |
dc.subject.emtree | Carbapenem derivative | en_US |
dc.subject.emtree | Cephalosporin derivative | en_US |
dc.subject.emtree | Ciprofloxacin | en_US |
dc.subject.emtree | Colistin | en_US |
dc.subject.emtree | Cotrimoxazole | en_US |
dc.subject.emtree | Doxycycline | en_US |
dc.subject.emtree | Hand sanitizer | en_US |
dc.subject.emtree | Metronidazole | en_US |
dc.subject.emtree | Penicillin derivative | en_US |
dc.subject.emtree | Quinolone derivative | en_US |
dc.subject.emtree | Rifampicin | en_US |
dc.subject.emtree | Tigecycline | en_US |
dc.subject.emtree | Antiinfective agent | en_US |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Aged | en_US |
dc.subject.mesh | Anti-bacterial agents | en_US |
dc.subject.mesh | Communicable diseases | en_US |
dc.subject.mesh | Cross-sectional studies | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | France | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Infection control | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Middle aged | en_US |
dc.subject.mesh | Patient care | en_US |
dc.subject.mesh | Tertiary care centers | en_US |
dc.subject.mesh | Turkey | en_US |
dc.subject.scopus | One Health Initiative; Curricula; University Teacher | en_US |
dc.subject.wos | Infectious diseases | en_US |
dc.subject.wos | Microbiology | en_US |
dc.title | The features of infectious diseases departments and anti-infective practices in France and Turkey: A cross-sectional study | en_US |
dc.type | Article | en_US |
dc.wos.quartile | Q2 | en_US |